Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.130
-0.020 (-1.74%)
At close: May 12, 2025, 4:00 PM
1.180
+0.050 (4.42%)
After-hours: May 12, 2025, 7:11 PM EDT
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
93.80M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRDL News
- 13 days ago - Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile Corp
- 26 days ago - Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 5 weeks ago - Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile Corp
- 2 months ago - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
- 2 months ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha
- 3 months ago - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 5 months ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire